{"page":{"totalFilteredElements":78},"studies":[{"active":true,"description":"GMMG HD9/ DSMM XVIII: A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma.","eudractNumber":"2023-507402-13","id":9091,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06216158","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-04-03T13:12:13+02:00","shortTitle":"DSMM XVIII [GMMG HD9]","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Ziel dieser multizentrischen, randomisierten, doppelblinden, aktiv-komparator-kontrollierten, adaptiven Phase-2/3-Studie ist die Entwicklung einer neuartigen Kombinationsimmuntherapie, EIK1001 + Pembrolizumab, für die Behandlung des Melanoms","eudractNumber":"2024-512659-19-00","id":11739,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"BRAF","id":"mt_9"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF V600","id":"mt_5"}],"nctNumber":"NCT06697301","phase":{"id":"ph_8","name":"Phase II/III"},"recruitmentStart":"2025-11-26T11:42:59+01:00","shortTitle":"EIK1001-006","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Randomized phase II trial for patients with newly diagnosed low-risk multiple myeloma to evaluate the benefit of 6 cycles of isatuximab with lenalidomide/ bortezomib/ dexamethasone (I-VRD) followd by maintenance therapy with lenalidomide and isatuximab randomized in comparison with therapy consisting of 3 cycles of I-VRD followd standard of care intensification followed by maintenance therapy with lenalidomide and isatuximab

Short title: Expression-linked and R-Iss-Adapted Stratification for first line therapy in multiple myeloma patients (ELIAS)
","eudractNumber":"2020-005102-26","id":9532,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05665140","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2024-07-01T12:46:18+02:00","shortTitle":"ELIAS","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued
Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
","eudractNumber":"2024-519827-16-00","id":11504,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06932562","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-11-10T09:57:13+01:00","shortTitle":"EMN 39","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Deutsches Nebennierenkarzinom Register -->
seit 17.06.2011:
Register und Biobank des Europäischen Netzwerks für Nebennierentumoren ENS@T (European Network for the Study of Adrenal Tumours)
","eudractNumber":null,"id":94,"indications":[{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2003-01-01T09:48:37+01:00","shortTitle":"ENSAT-Register","therapeutical":false,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"

 Surgery as\nneeded versus surgery on principle in patients with postneoadjuvant\nclinical complete tumor response of esophageal\ncancer - ESORES-Trial 

DRKS00022801

","eudractNumber":null,"id":10294,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-10-15T09:16:00+02:00","shortTitle":"ESORES","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A multinational registry for rhabdoid tumors of any anatomical site / EU-RHAB-Register (AT/RT)","eudractNumber":null,"id":232,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2010-11-15T10:59:53+01:00","shortTitle":"EU-RHAB","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Eine offene, forschungsinitiierte Phase I/II – Studie mit Venetoclax in Kombination mit Blinatumomab Immuntherapie bei erwachsenen Patienten mit rezidivierter/refraktärer ALL","eudractNumber":"2021-001384-25","id":9997,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD19","id":"mt_55"}],"nctNumber":"NCT05182385","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2022-02-14T11:58:28+01:00","shortTitle":"GMALL-BLIVEN","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"GPOH HD Study Registry 2.0
Prospective Registry for children and adolescents with classical Hodgkin Lymphoma, nodular lymphocyte-predominant Hodgkin Lymphoma and relapsed Hodgkin Lymphoma

","eudractNumber":null,"id":10077,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped2","name":"Lymphome"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2024-10-07T13:12:30+02:00","shortTitle":"GPOH HD Study Registry 2.0","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"International HIT-MED Registry: For children, adolescents, and adults \nwith medulloblastoma, ependymoma, pineoblastoma, CNS-primitive \nneuroectodermal tumours","eudractNumber":null,"id":1592,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"}],"mutations":[],"nctNumber":"NCT02417324","phase":null,"recruitmentStart":"2015-01-01T11:20:20+01:00","shortTitle":"I-HIT MED Registry","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}